Lactobacillus paracasei strain
US-12152232-B2 · Nov 26, 2024 · US
Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof
US9681666B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9681666-B2 |
| Application number | US-201615214685-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 20, 2016 |
| Priority date | Dec 24, 2013 |
| Publication date | Jun 20, 2017 |
| Grant date | Jun 20, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The antimicrobial effect of extracellular metabolite composition from Bacillus coagulans MTCC 5856 and composition comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis is described.
First claim
Opening claim text (preview).
We claim: 1. A process of microbial growth control, said process comprising the step of bringing into contact a microbial cell with a preparation consisting of extracellular metabolites of probiotic bacterial strain Bacillus coagulans deposited under accession number MTCC 5856, prepared by partially purifying a culture supernatant of said Bacillus coagulans strain, combined with a composition comprising from about 61% w/w of thymol, about 38% w/w of monolaurin, and about 1% w/w of magnolol, thereby inhibiting the growth of said microbial cell. 2. The process of claim 1 , wherein the microbial cell is one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli , and Salmonella abony.
Assignees
Inventors
Classifications
Animals; Substances produced thereby or obtained therefrom · CPC title
Oxygen or sulfur directly attached to an aromatic ring system · CPC title
Magnoliopsida [dicotyledons] · CPC title
containing the group [IMAGE cpc-sch-A01N-0932.gif], wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof · CPC title
- C12N1/20Primary
Bacteria; Culture media therefor · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9681666B2 cover?
- The antimicrobial effect of extracellular metabolite composition from Bacillus coagulans MTCC 5856 and composition comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis is described.
- Who is the assignee on this patent?
- Majeed Muhammed, Nagabhushanam Kalyanam, Arumugam Sivakumar, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C12N1/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).